New York Xeljanz Thrombosis Lawyers

Xeljanz (Tofacitinib) Pulmonary Embolisms

Have you or a loved one experienced a blood clot, deep vein thrombosis or pulmonary embolism while using Xeljanz sold by Pfizer? The drug was approved by the FDA in 2012. Xeljanz is one of the new “JAK Inhibitors” (janus kinase) used to treat moderate-to-severe active rheumatoid arthritis, psoriatic arthritis and moderate-to-severe active ulcerative colitis.

A Rheumatology Data Safety Monitoring Board stated in February 2019 that patients who received the 10 mg dose of Xeljanz were at a higher risk of pulmonary embolism and death, compared with patients in this study who were treated with a similar drug.

Our attorneys, Paul Rheingold and David Rheingold, have decades of litigation experience involving pulmonary embolism injuries, particularly with hormonal birth control, testosterone and inferior vena cava medical devices. Our firm has represented thousands of clients and gained millions of dollars in verdicts and settlements for other prescription drug cases.

Contact us to speak with a drug litigation partner from a
New York pharmaceutical litigation law firm.